Keywords: spectrum, cell, therapeutics, form, jv, projected, expansion

Spectrum and Cell Therapeutics form JV for projected expansion in US sales of Zevalin

Article | 08 December 2008

The USA's Spectrum Pharmaceuticals and Cell Therapeutics have formed a 50/50 joint venture to market Zevalin ([90Y]-ibritumomab tiuxetan) in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bayer

Biogen Idec

Go to company listing

Related Drugs

Ibritumomab Tiuxetan

Zevalin

Levoleucovorin

Aspirin

Bayer

Go to drug listing